Jefferies Group Weighs in on Hikma Pharmaceuticals Plc’s FY2017 Earnings (HKMPF)

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) – Investment analysts at Jefferies Group cut their FY2017 EPS estimates for shares of Hikma Pharmaceuticals in a research report issued on Monday. Jefferies Group analyst J. Vane-Tempest now anticipates that the company will earn $0.88 per share for the year, down from their prior estimate of $0.92. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Hikma Pharmaceuticals’ FY2018 earnings at $0.81 EPS, FY2019 earnings at $0.85 EPS, FY2020 earnings at $0.96 EPS and FY2021 earnings at $1.03 EPS.

Other analysts have also issued reports about the stock. Morgan Stanley restated an “equal weight” rating on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 8th. Zacks Investment Research lowered shares of Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Finally, Goldman Sachs Group lowered shares of Hikma Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold”.

Hikma Pharmaceuticals (HKMPF) opened at $13.60 on Tuesday. Hikma Pharmaceuticals has a 12-month low of $12.40 and a 12-month high of $27.50.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with's FREE daily email newsletter.

Leave a Reply